The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
Status:
Completed
Trial end date:
2021-07-02
Target enrollment:
Participant gender:
Summary
Adults who have tested positive for SARS-CoV-2 infection and who may require supplemental
oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in
addition to their normal care. Subjects will be be followed and assessed for their clinical
status over 28 days to see if PUL-042 Inhalation Solution improves the clinical outcome
Phase:
Phase 2
Details
Lead Sponsor:
Pulmotect, Inc.
Collaborator:
United States Department of Defense
Treatments:
Pam2CSK4 acetate and ODN M362 combination Pharmaceutical Solutions PUL-042